Literature DB >> 15001552

Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.

G Andringa1, K Y Lam, M Chegary, X Wang, T N Chase, M C Bennett.   

Abstract

In Parkinson's disease (PD), conformational changes in the alpha-synuclein monomer precede the formation of Lewy bodies. We examined postmortem PD and undiseased (control) substantia nigra for evidence of pathological crosslinking of alpha-synuclein by tissue transglutaminase (tTG) using immunohistochemistry, immunoprecipitation, and Western blot. Consistent with previous reports, we found that both tTG and its substrate-characteristic N(epsilon)-(gamma-glutamyl)-lysine crosslink are increased in PD nigral dopamine neurons. Furthermore, both the tTG protein and its substrate crosslink coprecipitated with alpha-synuclein in extracts of PD substantia nigra. Unexpectedly, the isodipeptide crosslink was detected in the alpha-synuclein monomer as well as in higher molecular mass oligomers of alpha-synuclein. Although the intramolecularly crosslinked alpha-synuclein monomer was present in control tissue, it was highly enriched in PD substantia nigra. Conversely, significantly less uncrosslinked alpha-synuclein remained in the postimmunoprecipitate lysate of PD tissue than in control. Crosslinked alpha-synuclein, formed at the expense of the total alpha-synuclein monomer, correlated with disease progression. These results demonstrate that much of the alpha-synuclein monomer in PD nigra is crosslinked by tTG and thus may be functionally impaired. This modification appears to be an early step in PD pathogenesis, preceding the aggregation of alpha-synuclein in Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001552     DOI: 10.1096/fj.03-0829fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  36 in total

Review 1.  The role of lipids in α-synuclein misfolding and neurotoxicity.

Authors:  Cathryn L Ugalde; Victoria A Lawson; David I Finkelstein; Andrew F Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

2.  Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.

Authors:  Thung-S Lai; Yusha Liu; Tim Tucker; Kurt R Daniel; David C Sane; Eric Toone; James R Burke; Warren J Strittmatter; Charles S Greenberg
Journal:  Chem Biol       Date:  2008-09-22

Review 3.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

4.  Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.

Authors:  Divya Mehta; Charles L Raison; Bobbi J Woolwine; Ebrahim Haroon; Elisabeth B Binder; Andrew H Miller; Jennifer C Felger
Journal:  Brain Behav Immun       Date:  2013-04-25       Impact factor: 7.217

5.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

6.  Phage display selection of efficient glutamine-donor substrate peptides for transglutaminase 2.

Authors:  Zsolt Keresztessy; Eva Csosz; Jolán Hársfalvi; Krisztián Csomós; Joe Gray; Robert N Lightowlers; Jeremy H Lakey; Zoltán Balajthy; László Fésüs
Journal:  Protein Sci       Date:  2006-11       Impact factor: 6.725

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

8.  Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases.

Authors:  Katrin Beyer; Montserrat Domingo-Sábat; José I Lao; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2007-10-23       Impact factor: 2.660

9.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.